Hydroxycarbamide: uses and safety

Hydroxycarbamide (hydroxyurea) is prescription-only. Ingredient identity.

Key takeaways

Exact-product instructions matter.
Report infection or bleeding.
Licences differ.

Evidence summary
Products
Mechanisms
Treatment monitoring
Supplements
Evidence and prescribing
Urgent care
Interactions
Reproductive precautions
Handling
Preclinical limits
Funding and source roles
Frequently asked questions
Sources and funding notes

Evidence summary

Clinical descriptions, care guidance and independently established treatment outcomes have different evidentiary roles. The table identifies what the reviewed sources can support and which financial or clinical questions remain unresolved.

Question / approach	Evidence reviewed	Funding / conflicts	Interpretation / limits
Products	Distinct licences	Maker labels	Check pack
Monitoring	Blood/organ review	SPS cites labels	Clinical plan
Comparisons	Selected ET trials	Connected authors / AOP sponsorship	No independent efficacy ranking
Popularity	England PCA items	Public administrative process	Not cancer patients/global demand

Products

Hydroxycarbamide inhibits ribonucleotide reductase, affecting DNA synthesis. Identity.

UK medac capsules: chronic/accelerated chronic myeloid leukaemia (CML), and high-thrombosis-risk essential thrombocythaemia (ET) or polycythaemia vera (PV). UK capsule scope.

UK Hydrea: pre-TKI CML before BCR-ABL confirmation requiring immediate count control; blastic-phase symptom relief; cervical cancer with radiotherapy. UK scope.

US Hydrea: resistant CML; locally advanced head-and-neck squamous cancer (excluding lip) with chemoradiation. US scope.

Mechanisms

Sickle-cell disease (SCD) tablets increase fetal haemoglobin (HbF), interfering with sickle-haemoglobin polymerization, and reduce blood-cell production. Mechanisms are incompletely understood; biology alone does not prove comparative benefit. SCD mechanism.

UK Xromi 100 mg/ml liquid prevents vaso-occlusive complications (vessel blockage) in sickle-cell disease (SCD) after nine months of age. Liquid scope.

UK Siklos 100 mg tablets cover symptomatic SCD after age two. They divide into two equal halves; follow the actual pack. Tablet scope.

Xromi holders: EU, Lipomed GmbH; UK, Nova Laboratories. EMA.

Treatment monitoring

Tyrosine kinase inhibitors (TKIs) underpin NHS CML care. A historical chemotherapy use or capsule licence is not a reason to replace the person’s current targeted-treatment plan. Disease phase and treatment goals matter. CML care.

Before treatment, clinicians review blood counts, kidney/liver function and other relevant tests. SCD requires additional disease-specific assessments. Starting, changing or stabilizing treatment calls for appropriate monitoring, with trends and individual circumstances considered. Monitoring.

Ask who assesses response and abnormal results. The specialist selects treatment.

Supplements

Complementary products must not delay or replace cancer treatment. Supplements can interfere with medicines; a natural label does not establish safety. Give the oncology team the exact product names before adding anything. Complementary-treatment safety.

Larger red cells (macrocytosis) can resemble B12/folate deficiency without causing it; ask the clinician. Macrocytosis.

US folic-acid prophylaxis needs clinician planning. Folate.

Nutrition support is individualized; supplements cannot replace prescribed treatment.

Evidence and prescribing

The 2018 PT-1 comparison involved adults aged 40–59 with ET without selected high-risk features. Its public/charitable funding and authors’ commercial ties are documented. This restricted population cannot settle every high-risk ET decision; no comparative efficacy verdict is adopted here. Original population.

ANAHYDRET was an AOP-sponsored trial in WHO-defined ET. Authors or institutions received remuneration. Its outcomes are excluded from this review’s independent efficacy verdict, irrespective of its randomized design. Original sponsorship.

England’s 2025/26 PCA Table 7 records 93,903 items under BNF 0801050P0 and a separate 561 under 0901030R0. Table 8 includes SCD-specific products within those coding groups. Items are not people or cancer-only use. Original tables.

The release was published on 4 June 2026 and concerns community dispensing in England. It excludes a global demand ranking and does not measure clinical effectiveness or all hospital medicine use. Dataset scope.

Financially limited comparisons do not prove treatment ineffectiveness. This review does not rank products.

Urgent care

Low blood counts can cause serious infection or bleeding. Contact the treating team immediately for fever, chills or other infection signs, unusual bleeding/bruising, black stools or bloody vomit. Follow the oncology team’s urgent pathway. Blood-count warning.

Painful/red/light-sensitive eyes or worsening vision need prompt medical/eye assessment: rare limbal stem-cell deficiency can threaten sight. Eye warning.

Report fever, cough or breathlessness promptly: possible serious lung toxicity. Clinicians assess haemolysis and ulcers/gangrene. US toxicity warnings.

Long-term therapy needs secondary-malignancy monitoring and skin sun protection. Follow-up precautions.

Nausea, vomiting, mouth sores, bowel symptoms, dizziness, drowsiness and skin/nail changes may occur. Report troublesome symptoms for review rather than assuming that toxicity shows treatment success. Leaflet effects.

Tongue/throat swelling, breathing or swallowing difficulty, collapse or inability to wake can signal anaphylaxis. Seek immediate emergency help; the NHS says call 999, or use the local emergency service elsewhere. Emergency allergy.

Interactions

Hydroxycarbamide can make some glucose sensors read falsely high, risking excess insulin and dangerous low glucose. Consult the diabetes team about compatible monitoring. FDA safety review.

Specialists review marrow-suppressants, radiotherapy, live vaccines and certain HIV medicines. Interactions.

Didanosine/stavudine combinations risk severe pancreatic/liver/nerve toxicity. Avoid live vaccines under the prescriber’s plan. US interaction context.

Review medicines with your prescriber.

Reproductive precautions

The medac leaflet excludes allergy or too-low blood counts. Report kidney/liver problems, gout and previous radiotherapy before treatment. Capsule assessment.

UK Xromi excludes pregnancy, breastfeeding, severe kidney/liver impairment, toxic marrow depression and concurrent antiretrovirals. Liquid exclusions.

UK Siklos excludes breastfeeding. Pregnancy and fertility planning require the specialist before treatment changes. Tablet reproductive warnings.

UK Hydrea permits pregnancy benefit–risk exceptions; clinicians decide between feeding and treatment. SmPC.

Medac’s leaflet prohibits breastfeeding; ask about differing SmPC wording. Leaflet.

US precautions: verify pregnancy, effective contraception, stop breastfeeding. Post-treatment precautions require specialist planning. US reproductive precautions.

Handling

Swallow the capsules whole; caregivers use gloves and wash hands. Pregnant, pregnancy-planning or breastfeeding people should not handle them. After excess intake, go immediately to the nearest hospital emergency department with the pack. Skip a missed Hydrea dose; never double. UK Hydrea leaflet.

US AHFS general missed-dose advice differs: take it when remembered unless near the next dose, without doubling. The actual prescription and product leaflet must resolve which instruction applies. US general instruction.

UK Xromi: supplied oral syringe; do not shake. Obtain cytotoxic-liquid handling/spill instructions; never convert capsule doses or concentrations yourself. Liquid handling.

If dizzy, do not drive/use machinery. No fixed safe-driving interval is supplied. Driving.

Agree monitoring, contact and medicine-change plans with the treating team.

Preclinical limits

Preclinical medac findings include genotoxicity and reproductive toxicity: hazards, not patient efficacy or a safe exposure. Preclinical context.

Preclinical findings cannot choose formulations or home doses, recommend supplements, or override human safety guidance.

Funding and source roles

Follow the money

Research funding at a glance

Funding & backersSource & studyClaim & limits

54 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.

Tier 10Reported independence

Tier 24Indirect ties

Tier 320Interested party

Tier 430Self-interested

Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.

The source-specific map separates documented institutional funding from disease-page payments and trial sponsorship. Unknown allocations remain unknown. A public agency, charity or academic address does not by itself establish independent treatment efficacy.

Source	Funding / backers	Country / jurisdiction	Independence	Credibility / incentives / gaps
NCI hydroxyurea dictionary	Writer and entry-specific payments unclosed. Institutional routes listed separately.	United States	Tier 2 — public identity context	B provisional. Synonyms and mechanism; no independent outcome ranking.
Hydrea SmPC	Neon Healthcare; payments unclosed.	UK; Hertford	Tier 4 — maker-produced label	D. Text 24 July 2026; emc 28 August 2026.
Hydrea leaflet	Neon Healthcare; payments unclosed.	UK; Hertford	Tier 4 — maker-produced label	D. July 2026 leaflet.
medac SmPC	medac GmbH; payments unclosed.	UK licence; Wedel, Germany	Tier 4 — maker-produced label	D. Text July 2025; emc 13 May 2026.
medac leaflet	medac GmbH; payments unclosed.	UK licence; Wedel, Germany	Tier 4 — maker-produced label	D. Text October 2024; emc 16 December 2025.
Xromi SmPC	Nova Laboratories; payments unclosed.	UK; Leicester	Tier 4 — maker-produced label	D. Text 28 July 2026; emc 5 August 2026.
UK Siklos SmPC	Theravia; preparation payments unknown.	UK licence; Neuilly-sur-Seine, France	Tier 4 — maker-produced label	D independence. Text 16 July 2026; emc 19 August 2026.
Waylis Hydrea label	Waylis distributor SPL; payments unclosed.	United States; Rahway, New Jersey	Tier 4 — maker-produced label	D. Posted 15 September 2025; text September 2025.
US H2 Hydrea SPL	H2 labeler; CHEPLAPHARM registrant; preparation payments unknown.	United States	Tier 4 — maker-produced label	D independence. Header 26 January 2026; archive 28 January; text December 2023.
FDA Hydrea/Droxia application	Public/industry-fee agency routes listed separately; application receipts unclosed.	United States	Tier 3 — fee-supported regulator	C provisional. WAYLIS THERAP record; status is not exclusive commercial-rights proof.
EMA Xromi record	Agency finance listed separately; product allocation and assessor interests unclosed.	European Union	Tier 3 — fee-supported regulator	C provisional. EU holder Lipomed GmbH; no efficacy clearance.
FDA CGM pharmacovigilance review	Agency funding listed separately; reviewer/project payments unclosed. Device-company material also examined.	United States	Tier 3 — incompletely cleared regulator	C provisional. June 2023 review; selected safety methods/conclusions, not all 68 pages or independent efficacy.
NHS CML treatment	Page/contributor finances unclosed. National policy listed separately.	United Kingdom	Tier 2 — public clinical context	C provisional. Reviewed 27 September 2023; due September 2026 passed.
AHFS hydroxyurea information	ASHP licensed publisher, NLM host; contributor payments unclosed. Publisher routes listed separately.	United States	Tier 3 — connected publishing route	C provisional. Revised 20 October 2024; country/product directions differ.
SPS hydroxycarbamide monitoring	SPS commissioning listed separately; bibliography includes maker labels. Contributor payments unclosed.	United Kingdom	Tier 3 — partly maker-derived context	C provisional. Updated 25 September 2026; monitoring guidance, not independent comparative outcomes.
PT-1 intermediate-risk trial	MRC, CRUK, French NCI, Bloodwise, Wellcome, Kay Kendall and LLS support; authors disclose industry employment, shares, fees and research.	UK-led; international authors	Tier 3 — commercially connected authors	C provisional. 2018 randomized selected-risk ET population; complete current funder/private receipts unclosed.
ANAHYDRET original trial	AOP Orphan Pharmaceuticals sponsored; authors/institutions remunerated, despite no-conflict wording.	Austria; international trial	Tier 4 — manufacturer-funded trial	D independence. 2013 WHO-defined ET trial; outcomes excluded.
NCCIH cancer complementary approaches	Acknowledged NCI/NCCIH reviewers; current personal/page allocations unclosed.	United States	Tier 2 — public safety context	C provisional. October 2021; interference and nonreplacement, not ingredient efficacy.
NHS anaphylaxis	Page/contributor finances unclosed. National policy listed separately.	United Kingdom	Tier 2 — public emergency context	C provisional. June 2023; June 2026 review due passed.
NHSBSA PCA publication	Agency finance listed separately; PCA allocation/contributor interests unclosed.	England, United Kingdom	Tier 3 — statistical process self-report	B provisional. Published 4 June 2026; community prescription items, not patients/global demand.
PCA 2025/26 original tables	NHSBSA original workbook; project allocation unclosed.	England, United Kingdom	Tier 3 — administrative data	B provisional. Tables 7–9 personally parsed; BNF codes do not isolate cancer patients.
NHSBSA 2025/26 annual report	DHSC sponsorship; Parliamentary and service-contract funding.	Newcastle, England, United Kingdom	Tier 3 — financial self-report	B provisional. July 2026; selected governance/finance, not full audit. Specific PCA payment chain unclosed.
Neon control filing	Neon Healthcare International reported ≥75% shares/votes and appointment rights.	Hertford, England, United Kingdom	Tier 4 — company-filed control	D self-interest. Current register read; ultimate contractual/backer chain unclosed.
Neon parent control filing	Anton Jonathan William Jenkins: >50%/<75% shares; Stephen Paul Knightley: >25%/≤50% shares/votes.	Hertford, England, United Kingdom	Tier 4 — company-filed control	D self-interest. Brackets, not exact current capitalization or all private funds.
Neon 2025 accounts	Medicine income; June 2025 group reorganization; subsequent HSBC secured facility. FY2025 identifies A Jenkins as ultimate control.	Hertford, England, United Kingdom	Tier 4 — company-filed finance	D self-interest. Selected scanned statements/notes read; not complete lender, product or reviewer allocations.
medac corporate profile	Privately owned medicine development/manufacturing/distribution business.	Wedel, Germany	Tier 4 — maker self-report	D self-interest. FY2024/25 sales context; beneficial owners, debts and product payments unclosed.
Nova corporate profile	Describes family/private funding, medicines and contract manufacturing.	Leicester, England, United Kingdom	Tier 4 — maker self-report	D self-interest. No full audit or product-specific allocation read.
Nova control filing	Nova Bio-Pharma Holdings reported ≥75% shares/votes.	Wigston, England, United Kingdom	Tier 4 — company-filed control	D self-interest. Reported parent; not full beneficial-owner chain.
Nova parent control filing	James/Peter White and Christopher Muryn: trust-related control; Regina White: share/vote control; Nova Nominees: appointment rights.	Wigston, England, United Kingdom	Tier 4 — company-filed control	D self-interest. Trust beneficiaries, exact percentages, lenders and private contracts unclosed.
Norgine completed Theravia purchase	14 August 2025 completed purchase; Theravia wholly owned by Norgine.	Netherlands entity; France subsidiary	Tier 4 — maker-produced announcement	D self-interest. Not a complete current cap table or Siklos payment ledger.
Norgine investment closing	15 December 2022 GSAM private-equity majority investment; Stein family retained significant stake.	Netherlands entity; international investor	Tier 4 — company-produced finance	D self-interest. Historical closing; current percentages, fund investors/debt unclosed.
Lipomed corporate profile	Privately owned pharmaceutical/API business; German GmbH and Swiss AG distinct.	Weil am Rhein, Germany; Arlesheim, Switzerland	Tier 4 — maker self-report	D self-interest. Ultimate private owners, product allocations and lenders unclosed.
Waylis corporate identity	Commercial medicines business; named shareholders/audited capital ledger unavailable.	Rahway, New Jersey, United States	Tier 4 — distributor self-report	D self-interest. Address read; no exclusive territorial contract inferred.
Waylis product catalogue	Lists Hydrea and Droxia; product-selling interests.	United States	Tier 4 — seller-produced catalogue	D self-interest. Catalogue is not stock, price, sole rights or comparative efficacy proof.
US H2 Pharma	Strategic product partnerships; private financial contracts unclosed.	Montgomery, Alabama, United States	Tier 4 — seller self-report	D self-interest. Shareholders and current rights unclosed; French H2 is a different entity.
CHEPLAPHARM history	Reports Braun-family acquisition and Hydrea purchase from BMS in March 2022.	Greifswald, Germany	Tier 4 — maker self-report	D self-interest. Historical transactions do not establish later Waylis/Droxia rights.
CHEPLAPHARM FY2025 results	Medicine-sales business; management results statement.	Greifswald, Germany	Tier 4 — company-produced finance	D self-interest. 29 April 2026; not full audited accounts/product payments.
CHEPLAPHARM creditor information	Bonds and term-loan instruments listed.	Germany	Tier 4 — company-produced finance	D self-interest. Selected current instrument records; no complete outstanding-debt/holder ledger.
GIC/Atlantic Park investment	October 2022 convertible investment; GIC and Atlantic Park.	Singapore; Germany investee	Tier 4 — investor-produced finance	D self-interest. Three-page original; no current conversion/cap-table claim.
Sanofi proposed CHEPLAPHARM transaction	Proposed 26.4% equity for medicines/sites; conditions and 2027 timing.	Paris, France; Germany investee	Tier 4 — company-produced announcement	D self-interest. 14 September 2026; not completed current ownership.
AOP corporate identity	Privately owned pharmaceutical company.	Vienna, Austria	Tier 4 — sponsor self-report	D self-interest. Own identity read; ultimate ownership/current complete funding unclosed.
NCI budget	Congressional appropriations through NIH/HHS.	United States	Tier 3 — financial self-report	B provisional. 14 May 2026; requests differ from enacted finance. Entry-specific allocation unclosed.
NCI gift fund	Conditional/unconditional donations permitted.	Bethesda, Maryland, United States	Tier 3 — financial self-report	B provisional. Donation authority is not proof of dictionary payment; exact donors unclosed.
NCCIH appropriations	Congressional appropriations; series through FY2024.	United States	Tier 3 — financial self-report	B provisional. Not current-year figures or page-allocation clearance.
NCCIH gift policy	Conditional/unconditional gift account, separate from appropriations.	Bethesda, Maryland, United States	Tier 3 — financial self-report	B provisional. Permission does not establish a named company’s clinical-page payment.
NHS content policy	DHSC site funding; no ads/corporate sponsorship stated.	United Kingdom	Tier 3 — process self-report	C provisional. October 2022; October 2025 review due passed. Not provider/individual finances.
NLM institutional identity	NIH institution; welcomes donations/bequests. Hosting is distinct from ASHP authorship.	Bethesda, Maryland, United States	Tier 3 — institutional self-report	B provisional. March 2026; individual gifts, licensed-page and author allocations unclosed.
ASHP 2026 Treasurer report	Programs/products/services and investments; FY2025 actual, FY2026 projected, FY2027 budget distinct.	Bethesda, Maryland, United States	Tier 3 — financial self-report	B provisional. Four-page report read; not full underlying audit or AHFS contributor ledger.
ASHP licensing	AHFS commercial licensing to healthcare/technology users.	United States	Tier 4 — seller-produced finance	D self-interest. Licensing route, not named hydroxyurea author payment.
ASHP corporate-support list	Named pharmaceutical/corporate support.	United States	Tier 3 — institutional finance self-report	C provisional. Displayed June 2019–May 2020 list is historical; current AHFS allocations unclosed.
SPS commissioning	Commissioned by NHS England.	United Kingdom	Tier 3 — institutional process self-report	B provisional. Service statement, not full agency accounts or contributor-payment clearance.
FDA FY2026 operating plan	Human-drug appropriations and industry user fees shown separately.	United States	Tier 3 — financial self-report	B provisional. Selected five-page plan tables; no product-specific receipts/invoices.
EMA 2025 annual report	Fees and EU contributions.	Amsterdam, Netherlands	Tier 3 — financial self-report	B provisional. Printed 78–79/contact selected; not full agency audit or assessor interests.
Norgine legal entities	Company-published legal identities; income and ownership routes are documented separately.	Norgine Europe B.V.: Netherlands	Tier 4 — company self-report	D self-interest. Current entity list read; listing does not resolve private investors, contracts or product allocation.

Frequently asked questions

Hydroxycarbamide or hydroxyurea? Same ingredient. Identity.

May I transfer capsule instructions to Xromi? No; follow its own indication, age and handling instructions. Xromi.

Can I change insulin after a high sensor reading? Ask the diabetes team. Hydroxycarbamide can produce falsely high sensor readings; do not change insulin from this article.

What if too much Hydrea was taken? Seek hospital emergency care immediately. Take the pack; do not wait for symptoms.

Can I breastfeed while taking medac capsules? The medac leaflet says no. Obtain specialist advice before use.

How much should I take? The specialist sets treatment and monitoring. This guide supplies no personal dose, conversion or stopping schedule.

Sources and funding notes

Recorded access scopes and remaining financial gaps are documented source by source.

Educational research reviewed 5 October 2026. Diagnosis and treatment require a qualified clinician; this article does not provide an individual prescription or replace urgent assessment.

Have a question — or want us to cover something?

Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.

One daily research roundup

Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.